Grounded in 19,841 PubMed abstracts (2017–2026). Get instant, cited answers.
FLT3 inhibitors, IDH1/IDH2 inhibitors, venetoclax combinations reshaping AML treatment.
TreatmentsNPM1, FLT3-ITD, IDH1/2, DNMT3A, TP53 — prognostic significance and therapeutic implications.
GenomicsRemission rates, overall survival, MRD monitoring, and long-term outcomes across patient populations.
OutcomesAllogeneic HSCT indications, conditioning regimens, GVHD, and post-transplant outcomes in AML.
TransplantCAR-T cells, checkpoint inhibitors, bispecific antibodies in relapsed/refractory AML.
ImmunologyLow-intensity regimens, azacitidine + venetoclax for older patients unfit for intensive chemo.
Special PopulationsGet instant, evidence-based answers from 19,841 PubMed abstracts. Local RAG retrieves the most relevant studies. A local LLM synthesizes clear, cited responses
PubMed abstracts are encoded into 384-dimensional semantic vectors using sentence-transformers. Questions retrieve top-K abstracts from a local FAISS ( (Facebook AI Similarity Search) index, then a local Ollama LLM generates a grounded, cited answer.
Browse PubMed →Get started in 3 commands:
pip install -r requirements.txt python build_index.py python server.pyGet Ollama →